Halozyme Therapeutics has announced a definitive agreement to acquire Elektrofi, a biopharmaceutical company known for its breakthrough ultra-high concentration biologics delivery platform, Hypercon™. The transaction includes an upfront payment of $750 million and up to three milestone payments of $50 million each, tied to regulatory approvals of separate products. The deal was unanimously approved by the boards of both companies.
Elektrofi’s Hypercon technology enables biologic drug formulations with concentrations of 400–500 mg/ml—four to five times higher than conventional formulations—while preserving smooth syringeability. This innovation allows for significantly reduced injection volumes, supporting more convenient at-home or in-office delivery options, including use with Halozyme’s high-volume auto-injector.
“This acquisition marks a pivotal step in Halozyme’s evolution,” said Dr. Helen Torley, President and CEO of Halozyme. She emphasized that the deal diversifies the company’s drug delivery platform offerings and supports long-term revenue growth through licensing and royalties from Elektrofi’s business model.
Elektrofi CEO and co-founder Chase Coffman said the acquisition advances the company’s mission of improving biologic drug delivery and strengthens its commercialization strategy by leveraging Halozyme’s established industry presence.
Following the acquisition, Halozyme plans to integrate Elektrofi’s team and technology to expand its reach in the biopharma sector and enhance treatment delivery options for patients.